AMAlexandra Murray

Alexandra Murray

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Murray has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IgG4 ‐Related Disease: A Diagnostic Dilemma for 20 Years

    by Alexandra Murray, Marlene Wijaya, Jennifer Kim, Jillian Wells

    We report a case of IgG4‐related disease in a 65‐year‐old man who remained undiagnosed for two decades. His disease initially manifested as periorbital oedema, followed by right cheek swelling, lymphadenopathy and a widespread pruritic eruption of skin‐coloured and pale erythematous papules. IgG4 was only considered after a stroke protocol MRI of the brain demonstrated an incidental finding of characteristic orbital manifestations. This case highlights the diagnostic complexity of IgG4‐related disease and emphasises the importance of recognising its varied presentations to facilitate early diagnosis and management.

  • Open Access

    National Income and Time-Related Changes in Childhood Blindness: A 50-Year Systematic Review and Meta-Analysis

    by Thomas Rogerson, Alexandra Murray, Robert J. Casson

    Background: The relationship between socioeconomic development and the prevalence and causes of childhood blindness has not been systematically quantified globally; we assessed income-related and temporal variation in its prevalence and aetiologyMethods: We conducted a systematic review and random-effects meta-analysis of studies reporting the prevalence and causes of childhood blindness and severe visual impairment (SVI) in individuals younger than 16 years, defined by ICD-11 criteria. MEDLINE, Embase, PubMed, and the Cochrane Database of Systematic Reviews were searched from Jan 1, 1970, to May 22, 2021. Eligible studies reported prevalence or causes of blindness or SVI; studies without clear visual acuity definitions or reporting single causes were excluded. Two reviewers independently screened studies, extracted data, and assessed risk of bias using Joanna Briggs Institute criteria. The primary outcomes were prevalence of blindness and proportional causes by income group and period. Pooled estimates were generated using random-effects meta-analysis. The protocol was registered with PROSPERO (CRD42022361015).Findings: There were 91 studies from 52 countries included, comprising 22 297 children with blindness for aetiological analyses and 8 548 555 children for prevalence analyses. The prevalence of childhood blindness differed by income group (p = 0·015), with the highest prevalence in middle-income countries (130·2 per 100 000 children) compared with low-income (64·0) and high-income countries (42·2). We estimated that 1·93 million children are blind globally, of whom 80·7% reside in low- and middle-income countries. Causes varied by income: anterior segment causes predominated in low-income settings, whereas posterior segment and visual pathway disorders were more common in higher-income settings. Substantial heterogeneity was observed across studies (I² > 75% for most analyses).Interpretation: Childhood blindness follows a development-associated epidemiological transition, with a shift from avoidable anterior segment disease to retinal and neurodevelopmental causes as countries undergo economic growth.

  • Safety and Efficacy of Angiotensin Receptor Antagonists in Recessive Dystrophic Epidermolysis Bullosa

    by Joseph Joseph, Alexandra Murray, Kelvin Truong, Artiene Tatian

    Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited progressive blistering skin disorder caused by mutations in the COL7A1 gene. Chronic wounds lead to cycles of scarring and healing, causing severe functional deformities. Losartan is an angiotensin II type 1 receptor (AT1R) antagonist that has been shown to have antifibrotic activity via inhibiting the production of transforming growth factor beta (TGF‐B) and has a favourable safety profile in children. In this systematic review, there were five studies found, with a total of 59 patients including case series, case–control and an open label phase 2 clinical trial. These studies have demonstrated the safety of losartan with no significant adverse effects such as hypotension, hyperkalaemia and hypersensitivity. They have also demonstrated evidence of efficacy utilising subjective assessments and objective criteria such as the Birmingham Epidermolysis Bullosa Severity score (BEBS) and Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Although safe and effective, further clinical trials are required to fully elucidate the role of this treatment; whether this approach should be standardised across the RDEB patient cohort is yet to be determined from the current evidence. Trial Registration: PROSPERO ID: CRD42024557126